|
[ back to press releases ]
Pervasis Therapeutics, Inc. Selected as a Finalist for the Red Herring 100, North America 2007
 Award Recognizes the 100 “Most Promising” Companies Driving the Future of Technology
Cambridge, Massachusetts – April 17, 2007 – Red Herring today announced that
Pervasis Therapeutics, Inc., a pioneer in regenerative cell-based therapies and
technologies, is a Finalist for the Red Herring 100 Award, a selection of the 100 private
companies based in North America that play a leading role in innovation and
technology.
The Red Herring editorial board diligently surveyed the entrepreneurial
scene throughout the North American region and identified the top 200 out of more
than 800 closely evaluated companies that are leading the next wave of innovation.
“We can see the exciting evolution of the technology sector reflected in the quality and
variety of exceptional companies that we had to choose from in putting our list
together," said Joel Dreyfuss, Editor-in-Chief of Red Herring. "It was tough to choose
just 200 finalists from such a large list of excellent contenders, and we are very happy
with the qualities of the companies we selected as Finalists."
Pervasis’ novel therapeutic technology, Vascugel™, is currently undergoing two Phase
II clinical trials in human subjects for end-stage renal disease (ESRD) who require
arteriovenous access for hemodialysis. Vascugel™ is an allogeneic cell therapy product
for enhancing repair and preventing clinical failure of vascular surgery and intervention.
Vascugel™ builds on concepts of tissue engineering to enable implantation of allogeneic
endothelial cells in a controlled state. When wrapped around an injured blood vessel,
Vascugel™ endothelial cells provide growth regulatory compounds to the underlying
blood vessel, promoting a natural healing process and preventing excessive scar tissue
formation, inflammation and thrombosis.
The winning 100 companies will be announced at the Red Herring Spring event. The
CEOs of the winners will present their innovative ideas and technologies to an audience
of leading entrepreneurs, financiers and corporate strategists at the event in Monterey,
California, on May 1-3 at the Hyatt Regency Hotel. This year’s Red Herring 100 Spring
event marks the 10th anniversary of the Red Herring 100 Awards. In celebration, the
event will feature keynote addresses from legendary VC investors and CEOs of leading
Internet, information, and communications companies. Request your invitation at:
http://www.herringevents.com/spring07/index.html
About Pervasis Therapeutics, Inc.
Pervasis Therapeutics, Inc. is a pioneer in regenerative cell-based therapies and
devices. Pervasis is currently developing technologies to restore natural blood flow to
critical organs. The company’s flagship product, Vascugel™, is a cell-based therapeutic
gel currently being developed to help reverse acute vascular injury.
Pervasis’ investors include Polaris Venture Partners, Flagship Ventures and Highland
Capital Partners. The company was founded by Elazer Edelman, Robert Langer, Joseph
Vacanti, and Helen Nugent.
For more information, please visit www.pervasistx.com.
About Red Herring
Red Herring is a global media company which unites the world’s best high
technology innovators, venture investors and business decision makers in a
variety of forums: a leading innovation magazine, an online daily technology
news service, technology newsletters and major events for technology
leaders around the globe. Red Herring provides an insider’s access to the
global innovation economy, featuring unparalleled insights on the emerging
technologies driving the economy. More information about Red Herring is
available on the Internet at www.redherring.com.
CONTACTS:
Pervasis Therapeutics Contact:
Michele Rozen
Pure Communications, Inc.
Email: michele@purecommunicationsinc.com
Phone: 617-730-8284
Red Herring Contact:
Olle Binkhorst
Red Herring, Inc.
Phone: 650-585-3418
Email: obinkhorst@redherring.com
[ back to top ]
|
